This study demonstrates that the FDA-approved drug 18AA potently resensitizes multidrug-resistant pathogens to ceftazidime-avibactam. It achieves this by activating two bacterial pathways, the inosine-CusS/R-CusC axis and the proton motive force, to promote antibiotic influx, offering a readily translatable strategy against formidable infections.